VOTRIENT 200 MG/*54745756836*/
VOTRIENT 200 MG
Categories: Anti-Diabetic, BEST SELLER, Breast Cancer, Colorectal Cancer, Diabetic, Endometrial Cancer, Liver Cancer, Lymphoma, ONCOLOGY PRODUCTS, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Primary Biliary Cirrhosis, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis
Tags: Afatinib Dimaleate INN, ALECNIB 150 MG, AXINIX, BARICINIX 4 MG, Baricinix Tablet, Beacon Pharmaceuticals Ltd., Cancer Medicine in Bangladesh, Oncology Medicine Supplier, Oncology Medicine Supplier in Bangladesh, Oncology Medicines in Bangladesh, VOTRIENT, VOTRIENT 200 MG
Reviews (0)
Be the first to review “VOTRIENT 200 MG” Cancel reply
Shipping & Delivery
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing/*54745756836*/
Related products
ACLOPAIN 100 MG
Indications Aceclofenac is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, toothache, trauma, and
CRIZOCENT 250 MG
Presentation Crizocent 250: Each capsule contains Crizotinib INN 250 mg Description Crizotinib is an inhibitor of receptor tyrosine kinases including
BARICINIX 2 MG
Product Description: Baricitinib is indicated for the treatment of moderate to severely active rheumatoid arthritis in adult patients who have
HERNIX 40 MG
Hernix Tablet Neratinib 40 mg Beacon Pharmaceuticals Ltd. Indications Neratinib is a kinase inhibitor indicated for the extended adjuvant treatment of
IBRUNIB 140 MG
IBRUNIB Strength 140 mg Packing 1 X 30 Capsules (Plastic Container) Storage Store below 30°C. Keep capsules in the original
CRIZONIX 250 MG
Crizonix Capsule 250 mg Indications Crizotinib is a kinase inhibitor indicated for the treatment of patients with- Metastatic non-small cell lung
CABOZANIX 80 MG
Product Description: Cabozanix is a multiple Tyrosine Kinase inhibitor that is indicated for the treatment of Renal Cell Carcinoma and
AXINIX 5 MG
DESCRIPTION Axinix (Axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one
Reviews
There are no reviews yet.